Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861357 | 0.80 | MRGPRX4 (0.55) | KEAP1NFE2L2 | |
| SCHEMBL1140188 | 0.76 | KEAP1 (0.71) | KEAP1NFE2L2 | |
| SCHEMBL6073753 | 0.75 | ESR1 (0.54) | KEAP1NFE2L2 | |
| SCHEMBL1629150 | 0.75 | KEAP1 (0.77) | KEAP1NFE2L2 | |
| SCHEMBL702692 | 0.73 | KEAP1 (0.68) | KEAP1NFE2L2 | |
| SCHEMBL6541169 | 0.72 | PTPN1 (0.50) | KEAP1NFE2L2 | |
| SCHEMBL5203737 | 0.70 | CYP19A1 (0.47) | — | |
| SCHEMBL15583923 | 0.70 | MAPT (0.70) | KEAP1NFE2L2 | |
| SCHEMBL5572766 | 0.69 | KEAP1 (0.75) | KEAP1NFE2L2 | |
| SCHEMBL17879684 | 0.69 | KEAP1 (0.56) | KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | KEAP1 1570/4885NFE2L2 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.